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Background
Despite the growing interest and use of MSK-US in children, its current use in paediatric rheumatology is not known.
Objectives
To identify the current use of MSK-US and the areas most suitable for its development and standardisation in paediatric rheumatology.
Methods
A questionnaire of 10 single or composite questions, including professional data, current use in daily practice, current clinical relevance of the main features of MSK-US, and areas for prospective development, has been sent to the members of PRINTO/PRES.
Results
92/389 (24%) answers have been collected from 37 countries. The responders are mainly pediatric rheumatologists (80%), have a long-lasting clinical experience in paediatric rheumatology (74% >10 years), and are more clinicians (>70%) than researchers (24%).
MSK-US is used in clinical practice by>90%: personally by 40%, 49% by the radiologist, 16% by the adult rheumatologist. The most relevant features of MSK-US are the high patient's acceptability (76%), the immediate improving of diagnosis of joint and soft tissue disease (73%), the assessment of synovitis and tendons/ tendons'sheaths (73% and 70%), and the support to imaging guided joint injections (67%). The anatomical sites best suited for MSK-US are hips (87%), ankles (78%), wrists (65%), knees (64%), and mid-foot (63%). MSK-US is considered important for diagnosis, therapy monitoring, and research (70%).
Conclusions
We identified the current use of MSK-US in paediatric rheumatology among the European network of PRINTO/PRES. The results outline the major reasons and areas of interest, useful for future steps towards a wider international standardized development of MSK-US in paediatric rheumatology. 
